Vistim Labs develops AI-powered software designed to analyze EEG data for point-of-care monitoring of dementia and related neurodegenerative conditions. The company’s platform focuses on correlating brain activity patterns with established biomarkers such as amyloid, tau, brain atrophy, and cognitive performance measures. Its approach emphasizes non-invasive, accessible monitoring to support early detection and disease tracking. Vistim Labs positions its technology within clinical research and neurodiagnostic contexts.

The technology processes EEG recordings using machine learning models to generate brain maps that reflect neural function and network integrity. These maps are analyzed in relation to molecular and structural biomarkers, providing insights into disease progression and therapeutic response. The platform is optimized for rapid assessment, enabling clinicians to obtain actionable information at the point of care. This approach prioritizes integration with existing clinical workflows and reproducibility of results.

Vistim Labs targets clinicians and researchers working on dementia diagnosis, monitoring, and treatment evaluation. The platform is intended to augment traditional biomarker assessment rather than replace invasive testing. Its positioning reflects growing interest in leveraging AI-driven EEG analysis as a scalable, non-invasive tool for monitoring neurodegenerative disease.